Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N.

J Clin Oncol. 2019 Oct 14:JCO1800794. doi: 10.1200/JCO.18.00794. [Epub ahead of print]

PMID:
31609670
2.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology.

J Immunother. 2019 May 15. doi: 10.1097/CJI.0000000000000268. [Epub ahead of print]

PMID:
31107372
3.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology.

J Immunother. 2019 Jun;42(5):175-179. doi: 10.1097/CJI.0000000000000268.

PMID:
31090656
4.

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!

Luherne C, Darrigade AS, Dutriaux C, Prey S, Milpied B.

JAAD Case Rep. 2019 Apr 28;5(5):422-423. doi: 10.1016/j.jdcr.2019.02.033. eCollection 2019 May. No abstract available.

5.

Dual Role of Doubly Reduced Arylboranes as Dihydrogen- and Hydride-Transfer Catalysts.

von Grotthuss E, Prey SE, Bolte M, Lerner HW, Wagner M.

J Am Chem Soc. 2019 Apr 10;141(14):6082-6091. doi: 10.1021/jacs.9b01998. Epub 2019 Mar 28.

PMID:
30875474
6.

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.

Leroy V, Gerard E, Dutriaux C, Prey S, Gey A, Mertens C, Beylot-Barry M, Pham-Ledard A.

Cancer Immunol Immunother. 2019 Apr;68(4):545-551. doi: 10.1007/s00262-019-02298-9. Epub 2019 Jan 19.

PMID:
30661086
7.

Selective CO2 Splitting by Doubly Reduced Aryl Boranes to Give CO and [CO3 ]2.

von Grotthuss E, Prey SE, Bolte M, Lerner HW, Wagner M.

Angew Chem Int Ed Engl. 2018 Dec 10;57(50):16491-16495. doi: 10.1002/anie.201811135. Epub 2018 Nov 12.

PMID:
30320950
8.

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

Dupuis F, Lamant L, Gerard E, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B.

Br J Cancer. 2018 Jul;119(2):193-199. doi: 10.1038/s41416-018-0168-9. Epub 2018 Jul 5.

9.

Immunotherapy-induced hypothyroidism A report of melanoma treated by ipilimumab and nivolumab.

Haissagerre M, Prey S, Lauro C, Rousset M, Georges A, Corcuff JB.

Ann Biol Clin (Paris). 2018 Jun 1;76(3):326-328. doi: 10.1684/abc.2018.1350.

PMID:
29862971
10.

Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo.

Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J.

J Am Acad Dermatol. 2018 Jan;78(1):e17-e18. doi: 10.1016/j.jaad.2017.08.028. No abstract available.

PMID:
29241800
11.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM.

Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

PMID:
29146737
12.

Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?

Chong JH, Prey S, Mya HT, Delarue A, Labreze C.

Br J Dermatol. 2018 Mar;178(3):e196-e197. doi: 10.1111/bjd.15966. Epub 2018 Jan 23. No abstract available.

PMID:
28886210
13.

Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.

Rousset M, Dutriaux C, Bosco-Lévy P, Prey S, Pham-Ledard A, Dousset L, Gérard E, Bouchet S, Canal-Raffin M, Titier K, Molimard M.

Clin Chim Acta. 2017 Sep;472:26-29. doi: 10.1016/j.cca.2017.07.012. Epub 2017 Jul 12.

PMID:
28709799
14.

An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.

Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, Molimard M.

Clin Chim Acta. 2017 Jul;470:8-13. doi: 10.1016/j.cca.2017.04.009. Epub 2017 Apr 12.

PMID:
28412197
15.

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.

Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, Taieb A, Dutriaux C, Prey S, Boniface K, Seneschal J.

J Am Acad Dermatol. 2017 May;76(5):863-870. doi: 10.1016/j.jaad.2016.10.044. Epub 2017 Jan 13.

PMID:
28094061
16.

Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review.

Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, Gautier S, Ortis V, Lafon M, Montagne A, Delarue A, Voisard JJ.

Pediatrics. 2016 Oct;138(4). pii: e20160353. Review.

17.

Safety of Propranolol Therapy for Severe Infantile Hemangioma.

Prey S, Voisard JJ, Delarue A, Lebbe G, Taïeb A, Leaute-Labreze C, Ezzedine K.

JAMA. 2016 Jan 26;315(4):413-5. doi: 10.1001/jama.2015.13969. No abstract available.

PMID:
26813215
18.

A randomized, controlled trial of oral propranolol in infantile hemangioma.

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ.

N Engl J Med. 2015 Feb 19;372(8):735-46. doi: 10.1056/NEJMoa1404710.

19.

Stay in NICU and infantile haemangioma development.

Gey A, Ezzedine K, Diallo A, Prey S, Dreyfus I, Maza A, Mazereeuw-Hautier J, Taïeb A, Léauté-Labrèze C.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):566-73. doi: 10.1111/jdv.12639. Epub 2014 Aug 4.

PMID:
25088718
20.

Mast cells as possible targets of propranolol therapy: an immunohistological study of beta-adrenergic receptors in infantile haemangiomas.

Prey S, Leaute-Labreze C, Pain C, Moisan F, Vergnes P, Loot M, Taieb A, Cario-Andre M.

Histopathology. 2014 Sep;65(3):436-9. doi: 10.1111/his.12421. Epub 2014 Jun 5. No abstract available.

PMID:
24666350
21.

Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris.

Eytan O, Qiaoli L, Nousbeck J, van Steensel MA, Burger B, Hohl D, Taïeb A, Prey S, Bachmann D, Avitan-Hersh E, Jin Chung H, Shemer A, Trau H, Bergman R, Fuchs-Telem D, Warshauer E, Israeli S, Itin PH, Sarig O, Uitto J, Sprecher E.

Br J Dermatol. 2014 May;170(5):1196-8. doi: 10.1111/bjd.12799. No abstract available.

PMID:
24359224
22.

Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.

Ahogo CK, Ezzedine K, Prey S, Colona V, Diallo A, Boralevi F, Taïeb A, Léauté-Labrèze C.

Br J Dermatol. 2013 Dec;169(6):1252-6. doi: 10.1111/bjd.12432.

PMID:
23662995
23.

IFAG and childhood rosacea: a possible link?

Prey S, Ezzedine K, Mazereeuw-Hautier J, Eschard C, Barbarot S, Boralevi F, Taïeb A, Léaute-Labrèze C; Groupe de Recherche Clinique en Dermatologie Pédiatrique.

Pediatr Dermatol. 2013 Jul-Aug;30(4):429-32. doi: 10.1111/pde.12137. Epub 2013 Apr 8.

PMID:
23560522
24.

Development and validation of the K-VSCOR for scoring Koebner's phenomenon in vitiligo/non-segmental vitiligo.

Diallo A, Boniface K, Jouary T, Seneschal J, Morice-Picard F, Prey S, Cario-André M, Mazereeuw-Hautier J, Taieb A, Ezzedine K.

Pigment Cell Melanoma Res. 2013 May;26(3):402-7. doi: 10.1111/pcmr.12065. Epub 2013 Jan 30.

PMID:
23302147
25.

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A.

Br J Dermatol. 2012 Nov;167(5):1138-44. doi: 10.1111/j.1365-2133.2012.11186.x. Epub 2012 Oct 5.

PMID:
23039171
26.

Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo.

Ezzedine K, Diallo A, Léauté-Labrèze C, Seneschal J, Boniface K, Cario-André M, Prey S, Ballanger F, Boralevi F, Jouary T, Mossalayi D, Taieb A.

Br J Dermatol. 2012 Sep;167(3):490-5. doi: 10.1111/j.1365-2133.2012.11002.x.

PMID:
22512840
27.

Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France.

Maza A, Richard MA, Aubin F, Ortonne JP, Prey S, Bachelez H, Beylot-Barry M, Bulai-Livideanu C, Lahfa M, Nougué J, Mengual X, Le Moigne M, Lauwers-Cances V, Paul C.

Br J Dermatol. 2012 Sep;167(3):643-8. doi: 10.1111/j.1365-2133.2012.10991.x. Epub 2012 Jul 5.

PMID:
22512545
28.

Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation pattern.

Ezzedine K, Diallo A, Léauté-Labrèze C, Seneschal J, Mossalayi D, AlGhamdi K, Prey S, Bouchtnei S, Cario-André M, Boralevi F, Jouary T, Taieb A.

Arch Dermatol. 2012 Apr;148(4):497-502. doi: 10.1001/archdermatol.2011.351.

PMID:
22508876
29.

[Photodynamic therapy for the treatment of extramammary Paget's disease].

Clément E, Sparsa A, Doffoel-Hantz V, Durox H, Prey S, Bonnetblanc JM, Caly H, Aubard Y, Bedane C.

Ann Dermatol Venereol. 2012 Feb;139(2):103-8. doi: 10.1016/j.annder.2011.10.414. Epub 2011 Dec 26. French.

PMID:
22325748
30.

Successful treatment of intravascular papillary endothelial hyperplasia (IPEH) by the beta-adrenergic antagonist nebivolol.

Prey S, Haberstroh G, Vergier B, Taïeb A, Wassef M, Ezzedine K, Léauté-Labrèze C.

Br J Dermatol. 2012 May;166(5):1147-9. doi: 10.1111/j.1365-2133.2011.10755.x. No abstract available.

PMID:
22122809
31.

[Anti-p200 pemphigoid: a spectacular response to dapsone].

Munsch C, Prey S, Joly P, Meyer N, Lamant L, Livideanu C, Viraben R, Paul C.

Ann Dermatol Venereol. 2011 Nov;138(11):739-42. doi: 10.1016/j.annder.2011.05.024. Epub 2011 Jul 22. French.

PMID:
22078034
32.

Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo.

Ezzedine K, Diallo A, Léauté-Labrèze C, Séneschal J, Prey S, Ballanger F, Alghamdi K, Cario-André M, Jouary T, Gauthier Y, Taieb A.

Br J Dermatol. 2012 Mar;166(3):539-44. doi: 10.1111/j.1365-2133.2011.10709.x.

PMID:
22032627
33.

Infantile haemangioma: part II. Risks, complications and treatment.

Léauté-Labrèze C, Prey S, Ezzedine K.

J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1254-60. doi: 10.1111/j.1468-3083.2011.04105.x. Epub 2011 May 14.

PMID:
21569113
34.

Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities.

Léauté-Labrèze C, Prey S, Ezzedine K.

J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1245-53. doi: 10.1111/j.1468-3083.2011.04102.x. Epub 2011 May 14.

PMID:
21569112
35.

Joint clinical and pathological review meetings improve patient care: a prospective evaluation in dermatology.

Gardinal-Galera I, Bulai Livideanu C, Lamant L, Viraben R, Meyer N, Mazereeuw-Hautier J, Maza A, Prey S, Nespoulous M, Paul C.

J Eur Acad Dermatol Venereol. 2011 Aug;25(8):928-32. doi: 10.1111/j.1468-3083.2010.03883.x. Epub 2010 Nov 4.

PMID:
21054572
36.

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature.

Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Maitre ML, Richard-Lallemand MA, Ortonne JP.

J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:31-5. doi: 10.1111/j.1468-3083.2009.03565.x. Review.

PMID:
20443998
37.

Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies.

Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP.

J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:23-30. doi: 10.1111/j.1468-3083.2009.03564.x. Review.

PMID:
20443997
38.

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.

Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP.

J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:17-22. doi: 10.1111/j.1468-3083.2009.03563.x. Review.

PMID:
20443996
39.

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.

Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Paul C, Richard-Lallemand MA, Ortonne JP, Aubin F.

J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:10-6. doi: 10.1111/j.1468-3083.2009.03562.x. Review.

PMID:
20443995
40.

Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.

Paul C, Gourraud PA, Bronsard V, Prey S, Puzenat E, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP.

J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:2-9. doi: 10.1111/j.1468-3083.2009.03561.x. Review.

PMID:
20443994
41.

Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?

Fauchais AL, Prey S, Ouatara B, Vidal E, Sparsa A.

J Eur Acad Dermatol Venereol. 2010 Jun;24(6):737-8. doi: 10.1111/j.1468-3083.2009.03455.x. Epub 2009 Nov 11. No abstract available.

PMID:
19925601
42.

Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?

Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T.

Br J Dermatol. 2010 Jan;162(1):74-9. doi: 10.1111/j.1365-2133.2009.09373.x. Epub 2009 Jun 22.

PMID:
19689477
43.

Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.

Lourari S, Prey S, Livideanu C, Jamard B, Lamant L, Cantagrel A, Paul C.

J Eur Acad Dermatol Venereol. 2009 Aug;23(8):967-8. doi: 10.1111/j.1468-3083.2008.03074.x. Epub 2009 Jan 29. No abstract available.

PMID:
19192017
44.

Management of congenital nevi at a dermatologic surgical paediatric outpatient clinic: consequences of an audit survey 1990-1997.

Mérigou D, Prey S, Niamba P, Loot M, Lepreux S, Boralevi F, Labrèze C, Vergnes P, Taïeb A.

Dermatology. 2009;218(2):126-33. doi: 10.1159/000182264. Epub 2008 Dec 6.

PMID:
19060469
45.

Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.

Prey S, Paul C.

Br J Dermatol. 2009 Mar;160(3):622-8. doi: 10.1111/j.1365-2133.2008.08876.x. Epub 2008 Oct 20. Review.

PMID:
18945303
46.

Infantile acne: a retrospective study of 16 cases.

Hello M, Prey S, Léauté-Labrèze C, Khammari A, Dreno B, Stalder JF, Barbarot S.

Pediatr Dermatol. 2008 Jul-Aug;25(4):434-8. doi: 10.1111/j.1525-1470.2008.00755.x.

PMID:
18789082
47.

[Calciphylaxis treated by cinacalcet: a medical alternative to parathyroidectomy].

Prey S, Sparsa A, Durox H, Allot V, Pommepuy I, Salem A, Roux C, Labrousse F, Bonnetblanc JM.

Rev Med Interne. 2009 Feb;30(2):186-9. doi: 10.1016/j.revmed.2008.04.017. Epub 2008 Jun 25. French.

PMID:
18582992
48.

Efalizumab-induced lupus-like syndrome.

Durox H, Sparsa A, Loustaud-Ratti V, Prey S, Gondran G, Manea P, Vidal E, Bedane C.

Acta Derm Venereol. 2008;88(3):270-1. doi: 10.2340/00015555-0393. No abstract available.

49.

[Cutaneous drug reactions induced by glycopeptides].

Prey S, Sparsa A, Boumediene A, Bonnetblanc JM, Weinbreck P, Denes E.

Med Mal Infect. 2007 May;37(5):270-4. Epub 2007 Apr 16. French.

PMID:
17434698
50.

Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept.

Prey S, Robert PY, Drouet M, Sparsa A, Roux C, Bonnetblanc JM, Bédane C.

Acta Derm Venereol. 2007;87(1):74-5. No abstract available.

Supplemental Content

Support Center